Financial reports
ARS
2023 FY
Annual report to shareholders
27 Mar 24
10-K
2023 FY
Annual report
20 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
27 Oct 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
24 Feb 22
Current reports
8-K
Other Events
23 Feb 24
8-K
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
15 Feb 24
8-K
Travere Therapeutics Provides Corporate Update and 2024 Outlook
8 Jan 24
8-K
Cost Associated with Exit or Disposal Activities
4 Dec 23
8-K
Travere Therapeutics Reports Third Quarter 2023 Financial Results
7 Nov 23
8-K
Other Events
21 Sep 23
8-K/A
Financial Statements and Exhibits
7 Sep 23
8-K
Completion of Acquisition or Disposition of Assets
5 Sep 23
8-K
Travere Therapeutics Reports Second Quarter 2023 Financial Results
3 Aug 23
8-K
Entry into a Material Definitive Agreement
17 Jul 23
Registration and prospectus
S-8
Registration of securities for employees
3 Aug 23
424B5
Prospectus supplement for primary offering
1 Mar 23
FWP
Free writing prospectus
28 Feb 23
424B5
Prospectus supplement for primary offering
27 Feb 23
S-8
Registration of securities for employees
18 Aug 22
424B5
Prospectus supplement for primary offering
9 Mar 22
FWP
Free writing prospectus
9 Mar 22
FWP
Free writing prospectus
8 Mar 22
424B5
Prospectus supplement for primary offering
8 Mar 22
S-3ASR
Automatic shelf registration
3 Sep 21
Proxies
DEFA14A
Additional proxy soliciting materials
27 Mar 24
DEF 14A
Definitive proxy
27 Mar 24
DEF 14A
Definitive proxy
13 Apr 23
DEF 14A
Definitive proxy
4 Apr 22
DEF 14A
Definitive proxy
16 Apr 21
PRE 14A
Preliminary proxy
6 Apr 21
DEF 14A
Definitive proxy
14 Apr 20
DEF 14A
Definitive proxy
4 Apr 19
DEF 14A
Definitive proxy
5 Apr 18
DEF 14A
Definitive proxy
14 Apr 17
Other
CT ORDER
Confidential treatment order
23 Nov 21
UPLOAD
Letter from SEC
29 Sep 20
CORRESP
Correspondence with SEC
21 Sep 20
UPLOAD
Letter from SEC
4 Sep 20
CT ORDER
Confidential treatment order
7 Jun 19
UPLOAD
Letter from SEC
9 Jul 18
CORRESP
Correspondence with SEC
5 Jul 18
UPLOAD
Letter from SEC
22 Jun 18
CT ORDER
Confidential treatment order
22 May 18
CT ORDER
Confidential treatment order
14 May 18
Ownership
4
Christopher R. Cline
12 Apr 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
MACQUARIE GROUP LTD
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
12 Feb 24
SC 13G
MORGAN STANLEY
9 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
4
Eric M Dube
2 Feb 24
4
WILLIAM E. ROTE
2 Feb 24